Recursion registers 3.2M shares of Class A common stock for resale by Tempus Labs

RECURSION PHARMACEUTICALS, INC.

3,225,902 shares registered for resale by Tempus Labs as payment for initial license fee under Master Agreement.
Prospectus supplement filed under effective shelf registration statement (Form S-3ASR) on December 15, 2023.
Shares were originally issued to Tempus in November 2023 per the Master Agreement described in prior Form 8-K.
Resale offering is exempt from registration under the Securities Act.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.